Patents Assigned to Allergan, Inc.
  • Patent number: 11208377
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: December 28, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • Patent number: 11203748
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: December 21, 2021
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Patent number: 11202853
    Abstract: The present specification discloses porogen compositions comprising a core material and shell material, methods of making such porogen compositions, methods of forming such porous materials using such porogen compositions, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: December 21, 2021
    Assignee: Allergan, Inc.
    Inventors: Futian Liu, Nicholas J Manesis, Xiaojie Yu, Athene W. Chan
  • Patent number: 11185641
    Abstract: Skin can be treated by piercing skin with a plurality of needles of an injection device and ejecting a dose of fluid therethrough. The device can include a housing, a plunger disposed in the housing, a cartridge disposed in the housing, and one or more dosing chambers. The plurality of needles can be coupled to the housing and be in fluid communication with the cartridge. Advancement of the plunger can cause a dose of fluid to be ejected from the plurality of needles.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: November 30, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Ethan Franklin, Dimitrios Stroumpoulis, Zachary Dominguez, Justin Schwab, Bastien Mandaroux, Edwin Kayda
  • Patent number: 11160630
    Abstract: A tissue expansion device can be implanted temporarily beneath skin of a patient and removed upon predetermined expansion of overlying tissue. The device can include an expandable shell having a smooth or glossy outer surface and an injection port. The expandable shell can form an expandable chamber and have an anterior portion and a posterior portion. The injection port can be coupled to the anterior portion of the shell and be in fluid communication with the chamber and configured to permit injection of fluid into the chamber from a hypodermic needle. The device can have a plurality of tabs coupled to the posterior portion of the shell having one or more colors or attributes. The device can also include an orientation indicator visible along the anterior portion of the shell for assisting a clinician and orienting the device during the implantation procedure.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: November 2, 2021
    Assignee: Allergan, Inc.
    Inventors: David J. Schuessler, Alberto J. Flores, Daniela Rodriguez, Luis M. Solano
  • Patent number: 11147878
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: October 19, 2021
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Publication number: 20210307947
    Abstract: An implantable device used in a gastric band system includes an access port, a tube coupled to the access port, and a shielding device covering a portion of the tube. The shielding device is positioned adjacent to the access port and covers the end of the tube coupled to the access port. The shielding device is made from a puncture resistant material, to protect the tube from puncture by a misplaced syringe needle inserted by a physician.
    Type: Application
    Filed: August 21, 2013
    Publication date: October 7, 2021
    Applicant: Allergan, Inc.
    Inventors: Ethan Franklin, Justin Schwab
  • Patent number: 11124786
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: September 21, 2021
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Patent number: 11117860
    Abstract: The present disclosure relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: September 14, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Tien T. Duong, Richard L. Beard, Michael E. Garst
  • Patent number: 11096958
    Abstract: Disclosed are antiseptic compositions for disinfecting tissues, in particular for ocular use. Methods and compositions disclosed herein include sodium chlorite, optionally in combination with a surfactant.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: August 24, 2021
    Assignee: Allergan, Inc.
    Inventors: James A. Burke, Richard S. Graham, Corine Ghosn, Alexandra Almazan, Michael Engles, Lakshmi Rajagopalan
  • Patent number: 11083685
    Abstract: Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically in the treatment of aged skin, and may include phosphatidylserine, vitamins, and other beneficial anti-aging ingredients.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: August 10, 2021
    Assignee: Allergan, Inc.
    Inventor: Alan David Widgerow
  • Patent number: 11077174
    Abstract: The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: August 3, 2021
    Assignee: Allergan, Inc.
    Inventors: Kenton B. Abel, Andrew M. Blumenfeld
  • Patent number: 11078085
    Abstract: The present disclosure generally relates to methods of preparing spherical salt particles for industrial, medical, and other uses. The methods can include combining the angular salt particles with a quantity of finishing media, for example, into a receptacle. Thereafter, the angular salt particles and the finishing media can be moved or agitated until the angular salt particles have a desired sphericity.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: August 3, 2021
    Assignee: Allergan, Inc.
    Inventors: David J. Schuessler, Alberto J. Flores-Pujol
  • Patent number: 11077053
    Abstract: Methods of using the alpha-2-adrenergic receptor agonist of Formula I: for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: August 3, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Mohammed Dibas, Daniel W. Gil, Wayne Chen, Miguel Alcantara
  • Patent number: 11078262
    Abstract: Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: August 3, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Patrick M. Hughes, Gerald W. DeVries, Robert T. Lyons, John T. Trogden, Scott M. Whitcup
  • Patent number: 11065428
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: July 20, 2021
    Assignee: Allergan, Inc.
    Inventors: Futian Liu, Xiaojie Yu, Lance E. Steward, Guang Wei Lu, Patrick M. Hughes, Sheshadri Neervannan
  • Patent number: 11046644
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: June 29, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 11045515
    Abstract: The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil, e.g. olive oil, sesame oil, corn oil etc.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 29, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Anuradha V. Gore, Robert S. Jordan, Kevin Krock, Chetan Pujara
  • Patent number: 11046756
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: June 29, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Patent number: D926984
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: August 3, 2021
    Assignee: Allergan, Inc.
    Inventors: David J. Schuessler, Alberto J. Flores, Daniela Rodriguez, Luis M. Solano